TW201707691A - Oral dissolving film for achieving fast onset of action, enhancing medicine availability, fully developing therapeutic effect and reducing side effects - Google Patents

Oral dissolving film for achieving fast onset of action, enhancing medicine availability, fully developing therapeutic effect and reducing side effects Download PDF

Info

Publication number
TW201707691A
TW201707691A TW104128011A TW104128011A TW201707691A TW 201707691 A TW201707691 A TW 201707691A TW 104128011 A TW104128011 A TW 104128011A TW 104128011 A TW104128011 A TW 104128011A TW 201707691 A TW201707691 A TW 201707691A
Authority
TW
Taiwan
Prior art keywords
flavor
gum
group
oral
mpa
Prior art date
Application number
TW104128011A
Other languages
Chinese (zh)
Other versions
TWI612978B (en
Inventor
shi-bin Xu
jia-jun Liao
Yi-Ru Zhu
Original Assignee
Teh Seng Pharmaceutical Mfg Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teh Seng Pharmaceutical Mfg Co Ltd filed Critical Teh Seng Pharmaceutical Mfg Co Ltd
Priority to TW104128011A priority Critical patent/TWI612978B/en
Publication of TW201707691A publication Critical patent/TW201707691A/en
Application granted granted Critical
Publication of TWI612978B publication Critical patent/TWI612978B/en

Links

Abstract

The present invention relates to an oral dissolving film, which employs the edible material, such as gelatin, pectin and hydroxyethyl cellulose, as thickener, so as to greatly reduce the consideration of material cost. The oral dissolving film made thereby may achieve fast onset of action, enhance the medicine bioavailability, fully develop the therapeutic effect of medicine, reduce the side effects, convenient for administration by children and elders, easy for carrying, storage, transportation, and may be prepared in a simple method to be suitable for mass production.

Description

口溶膜Mouth soluble film

本發明係關於一種藥劑或食用物,尤指一種口溶膜。The present invention relates to a medicament or food, especially an oral film.

臨床常用的口服製劑通常都是通過胃腸道黏膜吸收,對於在胃腸道中不穩定、有刺激性和首過效應(First pass effect)明顯的藥物,不宜口服給藥。如肽類藥物、普萘洛爾(Propranolol)、利多卡因(Lidocaine)和一些抗生素;過去這些藥物一般採用注射給藥,長期用藥給患者造成不便與痛苦。Oral preparations commonly used in clinical practice are usually absorbed through the gastrointestinal mucosa, and it is not suitable for oral administration for drugs which are unstable, irritating and have a first pass effect in the gastrointestinal tract. Such as peptide drugs, Propranolol (Propranolol), Lidocaine (Lidocaine) and some antibiotics; in the past these drugs were generally administered by injection, long-term medication caused inconvenience and pain to patients.

近年的研究表明,藥物經部份口腔黏膜吸收可以避免首過效應,提高生物利用度,達到全身治療的目的;同時,口腔黏膜給藥方法較簡便,患者易於接受。因此,利用這部份口腔黏膜吸收的口腔黏膜給藥新劑型開發研究,日易受到重視。Recent studies have shown that drug absorption through partial oral mucosa can avoid first-pass effects, improve bioavailability, and achieve systemic therapeutic goals. At the same time, oral mucosal drug delivery methods are simple and easy for patients to accept. Therefore, the development of new dosage forms for oral mucosal absorption by this part of oral mucosa has been paid more and more attention.

口腔黏膜黏附給藥系統是近年來發展的一種新型生物黏附給藥系統,是近年來藥劑學的研究熱點,它利用黏附性的聚合物為載體,通過載體的生物黏附作用,延長製劑在口腔的滯留時間而發揮局部療效和全身治療作用,可以避免藥物在胃腸道降解和肝臟的首過效應,提高藥物的生物利用度,同時具有緩釋和定位的優點,具有廣闊的應用前景。口溶膜(oral dissolving films, ODF)是一種新的藥物傳遞系統、載藥多聚體膜劑,其大小、形狀、厚度類似於郵票,將其置於舌上,在唾液中能快速溶解、釋放藥物。從2003年起,有超過80餘種產品在北美上市,InnoZen公司和諾華公司等研發並上市了多個治療感冒的口服速溶膜劑OTC產品,包括鹽酸苯海拉明膜劑、右美沙芬膜劑、薄荷醇膜劑等。2007年上市的口腔膜劑產品的總價值達到5億美元,預計2012年將達到20億美元;根據以往的增長趨勢,預計2015年將達到130億美元。藉由下述幾篇目前已知之先前技術(專利文獻),來觀察目前口溶膜之發展趨勢:Oral mucoadhesive drug delivery system is a new type of bioadhesive drug delivery system developed in recent years. It is a research hotspot in pharmacy in recent years. It uses adhesive polymer as a carrier to extend the preparation in the oral cavity through the bioadhesion of the carrier. The localization effect and systemic treatment effect of residence time can avoid the degradation of the drug in the gastrointestinal tract and the first-pass effect of the liver, improve the bioavailability of the drug, and have the advantages of sustained release and localization, and have broad application prospects. Oral dissolving films (ODF) is a new drug delivery system, drug-loaded multimer film, which is similar in size, shape and thickness to stamps. It is placed on the tongue and dissolves quickly in saliva. Release the drug. Since 2003, more than 80 products have been listed in North America. InnoZen and Novartis have developed and marketed a number of oral fast-dissolving OTC products for the treatment of colds, including diphenhydramine hydrochloride and dextromethorphan. Agent, menthol film, and the like. The total value of oral film products marketed in 2007 reached US$500 million and is expected to reach US$2 billion in 2012. According to past growth trends, it is expected to reach US$13 billion in 2015. The current development trend of the orally soluble film is observed by the following prior art known patent documents (patent literature):

先前技術一,由台灣之早期公開公報得知公開號200413026之專利案:LTS洛曼治療系統股份有限公司(LTS Lohmann Therapie-Systeme AG)發明一種多層化(雙層化結構或三層化結構)之經黏膜治療系統,該雙層化結構的系統係由背襯層(或稱作儲藏層)及黏膜黏著層(或稱作黏著層)所組成;該三層化結構的系統係由背襯層(包括一中間層及一邊界層)及黏膜黏著層所組成。該中間層及邊界層由活性物質、中性之聚甲基丙烯酸甲酯(Eudragit® NE 30 D, Röhm)、溶劑、助溶劑及顏料所組成;相異之處,在於該中間層不含有或僅含有少量顏料。該黏膜黏著層由10wt% 聚乙烯醇(Mowiol 28–99, Clariant)水溶液及聚(甲基乙烯醚馬來酸酐)(Gantrez® S-95, ISP)所組成。該邊界層、中間層及黏膜黏著層之溶液配製完成後,依序將邊界層塗佈於惰性支持物;待邊界層乾燥後、將中間層塗佈於邊界層;待中間層乾燥後、將黏膜黏著層塗佈於中間層、等待乾燥,便可製備得到多層化之經黏膜治療系統。該發明所使用之聚(甲基乙烯醚馬來酸酐),不屬於台灣衛生福利部食品藥物管理署(FDA)所列管之可供食品使用原料及食品添加物,且該共聚物價格昂貴;此外,該發明所使用之材料必須使用依序層合之方式,將邊界層塗佈於惰性支持物/待乾燥、中間層塗佈於邊界層/待乾燥、黏膜黏著層塗佈於中間層/待乾燥等多階段之作業,人員、製程及設備皆耗費極大之成本。Prior Art 1, the patent publication No. 200413026 was discovered by the early publication of Taiwan: LTS Lohmann Therapie-Systeme AG invented a multilayer (double layered structure or triple layered structure) The transmucosal treatment system consists of a backing layer (or called a reservoir layer) and a mucoadhesive layer (or an adhesive layer); the system of the three-layered structure is backed by a backing The layer (including an intermediate layer and a boundary layer) and the adhesive layer of the mucosa. The intermediate layer and the boundary of the active substance, a neutral of polymethyl methacrylate (Eudragit ® NE 30 D, Röhm ), solvents, cosolvents, and a pigment composed; different place, in that the intermediate layer does not contain or Contains only a small amount of pigment. The mucoadhesive layer consists of 10% by weight aqueous solution of polyvinyl alcohol (Mowiol 28-99, Clariant) and poly(methyl vinyl ether maleic anhydride) (Gantrez ® S-95, ISP). After the solution of the boundary layer, the intermediate layer and the mucoadhesive layer is completed, the boundary layer is sequentially applied to the inert support; after the boundary layer is dried, the intermediate layer is applied to the boundary layer; after the intermediate layer is dried, A multi-layered transmucosal treatment system can be prepared by applying a mucoadhesive layer to the intermediate layer and waiting for drying. The poly(methyl vinyl ether maleic anhydride) used in the invention is not a food-usable raw material and food additive listed in the Food and Drug Administration (FDA) of the Ministry of Health and Welfare of Taiwan, and the copolymer is expensive; In addition, the materials used in the invention must be applied in a sequential lamination manner, the boundary layer is applied to the inert support/to be dried, the intermediate layer is applied to the boundary layer/to be dried, and the mucoadhesive layer is applied to the intermediate layer/ For multi-stage operations such as drying, personnel, processes and equipment are costly.

先前技術二,由台灣之早期公開公報得知公開號200502008,帝國製藥股份有限公司(Teikoku Seiyaku Co., Ltd.)發明一種含吩坦尼(fentanyl)之口腔黏膜貼附劑,該口腔黏膜貼附劑係由襯墊(PET film)、劑層、載層及載體(PLA fibers)所組成。該劑層由甲基乙烯基醚-馬來酸酐共聚物之80%乙醇溶液、羥丙基纖維素(黏度:150~400 mP・S)之乙醇溶液、甘油、聚乙二醇400、N-甲基-2-吡咯烷酮及檸檬酸吩坦尼所組成;該載層由乙基纖維素之乙醇溶液、羥丙基甲基纖維素2910之50%乙醇溶液、蓖麻子油及氧化鈦之乙醇分散液所組成。劑層與載層之溶液配製完成後,依序將劑層塗佈於襯墊;待劑層乾燥後、將載層塗佈於劑層;將載體黏著於載層、等待乾燥,便可製備得到含吩坦尼之口腔黏膜貼附劑。該發明所使用之甲基乙烯基醚-馬來酸酐共聚物,不屬於衛生福利部食品藥物管理署(FDA)所列管之可供食品使用原料及食品添加物,且該共聚物價格昂貴;此外,該發明所使用之材料使用依序層合之方式,將劑層塗佈於襯墊/待乾燥、載層塗佈於劑層、載層黏著於載體/待乾燥等多階段之作業,人員、製程及設備皆耗費極大之成本。Prior Art 2, known from Taiwan's Early Public Gazette, Publication No. 200502008, Teikoku Seiyaku Co., Ltd. invented an oral mucosal patch containing fentanyl, which is attached to the oral mucosa. The applicator consists of a PET film, a layer of the agent, a carrier layer and a carrier. The agent layer is composed of 80% ethanol solution of methyl vinyl ether-maleic anhydride copolymer, hydroxypropyl cellulose (viscosity: 150-400 mP·S) in ethanol solution, glycerin, polyethylene glycol 400, N- Methyl-2-pyrrolidone and phenantiryl citrate; the carrier layer is dispersed in ethanol solution of ethyl cellulose, 50% ethanol solution of hydroxypropyl methylcellulose 2910, castor oil and titanium oxide. The composition of the liquid. After the solution of the agent layer and the carrier layer is prepared, the agent layer is sequentially applied to the liner; after the layer is dried, the carrier layer is applied to the agent layer; the carrier is adhered to the carrier layer, and is dried, and then prepared. An oral mucosal patch containing fentanyl was obtained. The methyl vinyl ether-maleic anhydride copolymer used in the invention is not a food-usable raw material and food additive listed in the Food and Drug Administration (FDA) of the Ministry of Health and Welfare, and the copolymer is expensive; In addition, the materials used in the invention are applied in a sequential lamination manner, and the agent layer is applied to a plurality of stages such as a liner/to be dried, a carrier layer applied to the agent layer, and a carrier layer adhered to the carrier/to be dried. People, processes and equipment are costly.

先前技術三,由台灣之早期公開公報得知公開號200514579,史密斯克萊美公司(Smithkline Beecham Corporation)發明一種口用溶解薄膜,該口用溶解薄膜所使用之材料係由腸內聚合物層及緩衝層所組成;Prior Art 3, known from Taiwan's Early Public Gazette, Publication No. 200514579, Smithkline Beecham Corporation invented an oral dissolution film which is used for the dissolution of the film from the intestinal polymer layer and a buffer layer;

先前技術四,由台灣之早期公開公報得知公開號200906451琳得科股份有限公司(Lintec Corporation)發明一種經口投予劑及其製造方法,該經口投予劑係由凝膠形成層、藥物含有層及凝膠形成層所組成;Prior Art 4, known from the early publication of Taiwan, publication No. 200906451, Lintec Corporation, invented an oral administration agent and a method for producing the same, which is formed by a gel forming layer, a drug-containing layer and a gel-forming layer;

先前技術五,由台灣之專利公報得知發明公告第404838號專利,財團法人製藥工業技術研究發展中心發明一種口腔黏膜用藥長效劑型基劑,該口腔黏膜用藥長效劑型基劑係由黏著層與底層所組成;According to the prior art 5, the patent publication No. 404838 of the invention is known from the patent publication of Taiwan. The pharmaceutical industry technology research and development center invents a long-acting agent base for oral mucosa, and the long-acting base of the oral mucosa is composed of an adhesive layer. Composed of the bottom layer;

先前技術三-五之專利文獻也都使用依序層合之方式進行製備,在人員、製程及設備皆耗費極大之成本。The patent documents of the prior art three-five are also prepared by sequential lamination, which is extremely costly in personnel, process and equipment.

有鑑於先前技術之問題,本發明人認為應有一種改善之物質產生,為此設計一種口溶膜(an oral dissolving films),包括:In view of the problems of the prior art, the inventors believe that there should be an improved substance production, for which an oral dissolving film is designed, including:

第一增稠劑:介於0.1~5wt%;First thickener: between 0.1 and 5 wt%;

係選自於羧甲基纖維素鈉(sodium carboxymethyl cellulose, CMC-Na)、甲基纖維素(methyl cellulose, MC)、羥乙基纖維素(hydroxyethyl cellulose, HEC)、羥丙基纖維素(hydroxypropyl cellulose, HPC)、羥丙基甲基纖維素(hydroxypropyl methyl cellulose, HPMC)、微晶纖維素(microcrystalline cellulose)、變性澱粉(modified starch)、聚丙烯酸鈉(sodium polyacrylate)或聚乙烯吡咯烷酮(polyvinyl pyrrolidone, PVP)群組中之其一;It is selected from sodium carboxymethyl cellulose (CMC-Na), methyl cellulose (MC), hydroxyethyl cellulose (HEC), hydroxypropyl cellulose (hydroxypropyl). Cellulose, HPC), hydroxypropyl methyl cellulose (HPMC), microcrystalline cellulose, modified starch, sodium polyacrylate or polyvinyl pyrrolidone , PVP) one of the groups;

第二增稠劑:介於0.1~10wt%;Second thickener: between 0.1 and 10 wt%;

係選自於明膠(gelatin)、乾酪素(casein)、酪蛋白酸鈉(sodium caseinate)、甲殼素(chitin)、殼聚糖(chitosan)、乳清分離蛋白(whey protein isolate)、乳清濃縮蛋白(whey protein concentrate)、魚膠(isinglass)、黃原膠(xanthan gum)、結冷膠(gellan gum)、茁黴多糖(pullulan)、凝結多糖(condensation polysaccharide)、酵母多糖(zymosan)、瓊脂(agar)、卡拉膠(carrageenan)、海藻酸(鹽)(alginic acid (salt))、海藻酸丙二醇酯(propylene glycol alginate)、紅藻膠(furcellaran)或岩藻聚糖硫酸酯(fucoidan);Is selected from the group consisting of gelatin, casein, sodium caseinate, chitin, chitosan, whey protein isolate, whey concentrate Whey protein concentrate, isinglass, xanthan gum, gellan gum, pullulan, condensation polysaccharide, zymosan, agar (agar), carrageenan, alginate (salt), propylene glycol alginate, furcellaran or fucoidan;

膠凝劑:介於0.1~10wt%;Gelling agent: between 0.1~10wt%;

係選自於瓜爾豆膠(guar gum)、刺槐豆膠(locust bean gum)、羅望子膠(tamarind gum)、亞麻籽膠(flaxseed gum)、皂莢豆膠(honey locust gum)、阿拉伯膠(acacia gum)、黃蓍膠(tragacanth gum)、印度樹膠(Indian gum)、刺梧桐膠(karaya gum)、桃膠(peach gum)、果膠(pectin)、魔芋膠(konjac glucomannan, KGM)、印度蘆薈萃取液(India aloe extract)、菊糖(synanthrin) 或仙草多糖(mesona chinensis polysaccharide);以及效果成份及水補足至100%。It is selected from the group consisting of guar gum, locust bean gum, tamarind gum, flaxseed gum, honey locust gum, gum arabic ( Acacia gum), tragacanth gum, Indian gum, karaya gum, peach gum, pectin, konjac glucomannan, KGM, India Aloe extract (india aloe extract), inulin (synanthrin) or mesona chinensis polysaccharide; and the effect ingredients and water to make up to 100%.

與上述專利文獻比較,本發明所使用之原料方便取得、製造加工容易、價格成本低廉;再者,由於使用前述原料,因此本發明僅透過簡易製程,即將第一增稠劑(羥乙基纖維素)、第二增稠劑(明膠)、膠凝劑(果膠)、效果成份(含活性物質及其它成份)及無菌水,經(1)均質化、(2)超音波震盪、(3)加熱溶解及(4)均質化/除氣,四個步驟混合均勻後,便可以進行塗佈作業;本發明不需要使用到依序層合之方式,僅需要使用單層塗佈之方式即可以得到,經烘乾、切片後,便可以製備得到本發明所述之口溶膜。此外,依據本發明所製得之產品,可以表現其優點在於:(1)該口溶膜放置於口腔內,其黏附性十分良好;(2)該口溶膜可以含一種或一種以上之活性物質,且其藥物釋放性良好;(3)藥物釋放性也可以藉由對於第一增稠劑/第二增稠劑/膠凝劑之比例加以調整,即可以簡易而快速之製備而得到一速釋型(immediate-release type)或一緩釋型 (sustained-release type)之口溶膜。進而製備得到含一種或一種以上活性物質之一速釋型或一緩釋型口溶膜;分別適合不同之需求。向廣大患者和醫務工作者提供一種起效迅速、能提高藥物的生物利用度,充份地發揮藥物療效、減少不良反應、方便幼童和老年人減量服用,便於攜帶、貯存、運輸、製備方法簡單,適合大規模生產的新製劑。Compared with the above patent documents, the raw materials used in the present invention are convenient to obtain, easy to manufacture and process, and low in cost. Further, since the above raw materials are used, the present invention is only a simple process, that is, a first thickener (hydroxyethyl fibers). (), second thickener (gelatin), gelling agent (pectin), effect components (including active substances and other ingredients) and sterile water, (1) homogenization, (2) ultrasonic shock, (3 ) heating dissolution and (4) homogenization/degassing, after four steps of mixing, the coating operation can be carried out; the invention does not need to use the sequential lamination method, and only needs to use a single layer coating method. It can be obtained that after drying and slicing, the orally dissolvable film of the present invention can be prepared. In addition, the product prepared according to the present invention can exhibit the advantages of: (1) the oral film is placed in the oral cavity, and the adhesion is very good; (2) the oral film can contain one or more activities. a substance, and its drug release property is good; (3) drug release property can also be adjusted by the ratio of the first thickener/second thickener/gelling agent, that is, it can be prepared simply and quickly. An immediate-release type or a sustained-release type of orally soluble film. Further, an immediate release type or a sustained release type oral solution film containing one or more active substances is prepared; respectively, which are suitable for different needs. Provide a rapid onset of action to the majority of patients and medical workers, improve the bioavailability of drugs, fully exert drug efficacy, reduce adverse reactions, facilitate the reduction of young children and the elderly, easy to carry, store, transport, and prepare methods Simple, new formulation for mass production.

no

no

以下說明本發明之內容、特色與實施例,俾使貴審對於本案有進一步之理解。The content, features and embodiments of the present invention are described below, so that the trial has a further understanding of the present case.

本發明係一種口溶膜(an oral dissolving films),包括:The present invention is an oral dissolving film comprising:

第一增稠劑:介於0.1~5wt%;First thickener: between 0.1 and 5 wt%;

係選自於羧甲基纖維素鈉(sodium carboxymethyl cellulose, CMC-Na)、甲基纖維素(methyl cellulose, MC)、羥乙基纖維素(hydroxyethyl cellulose, HEC)、羥丙基纖維素(hydroxypropyl cellulose, HPC)、羥丙基甲基纖維素 (hydroxypropyl methyl cellulose, HPMC)、微晶纖維素(microcrystalline cellulose)、變性澱粉(modified starch)、聚丙烯酸鈉(sodium polyacrylate)或聚乙烯吡咯烷酮 (polyvinyl pyrrolidone, PVP)群組中之其一;It is selected from sodium carboxymethyl cellulose (CMC-Na), methyl cellulose (MC), hydroxyethyl cellulose (HEC), hydroxypropyl cellulose (hydroxypropyl). Cellulose, HPC), hydroxypropyl methyl cellulose (HPMC), microcrystalline cellulose, modified starch, sodium polyacrylate or polyvinyl pyrrolidone , PVP) one of the groups;

第二增稠劑:介於0.1~10wt%;Second thickener: between 0.1 and 10 wt%;

係選自於明膠(gelatin)、乾酪素(casein)、酪蛋白酸鈉(sodium caseinate)、甲殼素(chitin)、殼聚糖(chitosan)、乳清分離蛋白(whey protein isolate)、乳清濃縮蛋白(whey protein concentrate)、魚膠(isinglass)、黃原膠(xanthan gum)、結冷膠(gellan gum)、茁黴多糖(pullulan)、凝結多糖(condensation polysaccharide)、酵母多糖(zymosan)、瓊脂(agar)、卡拉膠(carrageenan)、海藻酸(鹽)(alginic acid (salt))、海藻酸丙二醇酯(propylene glycol alginate)、紅藻膠(furcellaran) 或岩藻聚糖硫酸酯(fucoidan);Is selected from the group consisting of gelatin, casein, sodium caseinate, chitin, chitosan, whey protein isolate, whey concentrate Whey protein concentrate, isinglass, xanthan gum, gellan gum, pullulan, condensation polysaccharide, zymosan, agar (agar), carrageenan, alginic acid (salt), propylene glycol alginate, red algae (furcellaran) or fucoidan (fucoidan);

膠凝劑:介於0.1~10wt%;Gelling agent: between 0.1~10wt%;

係選自於瓜爾豆膠(guar gum)、刺槐豆膠(locust bean gum)、羅望子膠(tamarind gum)、亞麻籽膠(flaxseed gum)、皂莢豆膠(honey locust gum)、阿拉伯膠(acacia gum)、黃蓍膠(tragacanth gum)、印度樹膠(Indian gum)、刺梧桐膠(karaya gum)、桃膠(peach gum)、果膠(pectin)、魔芋膠(konjac glucomannan, KGM)、印度蘆薈萃取液(India aloe extract)、菊糖(synanthrin) 或仙草多糖(mesona chinensis polysaccharide);It is selected from the group consisting of guar gum, locust bean gum, tamarind gum, flaxseed gum, honey locust gum, gum arabic ( Acacia gum), tragacanth gum, Indian gum, karaya gum, peach gum, pectin, konjac glucomannan, KGM, India Indica aloe extract, synanthrin or mesona chinensis polysaccharide;

以及效果成份及水補足至100%。And the effect ingredients and water make up to 100%.

由前述可知本發明所使用之原料方便取得、製造加工容易、價格成本低廉;再者,由於使用前述原料,因此本發明僅透過簡易製程,即將第一增稠劑(羥乙基纖維素)、第二增稠劑(明膠)、膠凝劑(果膠)、效果成份(含活性物質及其它成份)及無菌水,經(1)均質化、(2)超音波震盪、(3)加熱溶解及(4)均質化/除氣,四個步驟混合均勻後,便可以進行塗佈作業;本發明不需要使用到依序層合之方式,僅需要使用單層塗佈之方式即可以得到,經烘乾、切片後,便可以製備得到本發明所述之口溶膜。此外,依據本發明所製得之產品,可以表現其優點在於:(1)該口溶膜放置於口腔內,其黏附性十分良好;(2)該口溶膜可以含一種或一種以上之活性物質,且其藥物釋放性良好;(3)藥物釋放性也可以藉由對於第一增稠劑/第二增稠劑/膠凝劑之比例加以調整,即可以簡易而快速之製備而得到一速釋型(immediate-release type)或一緩釋型(sustained-release type)之口溶膜。進而製備得到含一種或一種以上活性物質之一速釋型或一緩釋型口溶膜;分別適合不同之需求。向廣大患者和醫務工作者提供一種起效迅速、能提高藥物的生物利用度,充份地發揮藥物療效、減少不良反應、方便幼童和老年人減量服用,便於攜帶、貯存、運輸、製備方法簡單,適合大規模生產的新製劑。It can be seen from the foregoing that the raw materials used in the present invention are easy to obtain, easy to manufacture and process, and low in cost. Further, since the above raw materials are used, the present invention is only a simple process, that is, a first thickener (hydroxyethyl cellulose), Second thickener (gelatin), gelling agent (pectin), effect components (including active substances and other ingredients) and sterile water, (1) homogenization, (2) ultrasonic vibration, (3) heat dissolution And (4) homogenization/degassing, after the four steps are uniformly mixed, the coating operation can be performed; the invention does not need to be used in the sequential lamination manner, and only needs to be obtained by using a single layer coating method. After drying and slicing, the orally dissolvable film of the present invention can be prepared. In addition, the product prepared according to the present invention can exhibit the advantages of: (1) the oral film is placed in the oral cavity, and the adhesion is very good; (2) the oral film can contain one or more activities. a substance, and its drug release property is good; (3) drug release property can also be adjusted by the ratio of the first thickener/second thickener/gelling agent, that is, it can be prepared simply and quickly. An immediate-release type or a sustained-release type of orally soluble film. Further, an immediate release type or a sustained release type oral solution film containing one or more active substances is prepared; respectively, which are suitable for different needs. Provide a rapid onset of action to the majority of patients and medical workers, improve the bioavailability of drugs, fully exert drug efficacy, reduce adverse reactions, facilitate the reduction of young children and the elderly, easy to carry, store, transport, and prepare methods Simple, new formulation for mass production.

本發明更具體之實施例其中該效果成份包括第一甜味劑,該第一甜味劑係選自於玉米糖漿、半乳糖、乳糖、麥芽糖、山梨醇、以酵素轉化之玉米糖漿、葡萄糖、麥芽糖醇、蔗糖、木糖醇、果糖、環己基(代)磺醯胺酸、阿斯巴甜、乙醯磺胺酸鉀、甜菊糖苷、羅漢果、糖精、蔗糖素或5-硝基-2-丙氧基苯胺及紐甜,透過該第一甜味劑賦予一種口溶膜之清甜口感,增加其味覺的感受,修飾或減少苦澀的味覺感受。In a more specific embodiment of the present invention, the effect component comprises a first sweetener selected from the group consisting of corn syrup, galactose, lactose, maltose, sorbitol, corn syrup transformed with an enzyme, glucose, Maltitol, sucrose, xylitol, fructose, cyclohexyl sulfonamide, aspartame, potassium sulfamate, stevioside, mangosteen, saccharin, sucralose or 5-nitro-2-propanol The oxyaniline and neotame impart a sweet taste to the orally soluble film through the first sweetener, increase the taste sensation, and modify or reduce the taste sensation of bitterness.

本發明更具體之實施例其中該效果成份更包括第二甜味劑,該第二甜味劑為海藻糖,透過該第二甜味劑,可以賦予一種口溶膜之結晶抑制功效,抑制薄荷的結晶產生。In a more specific embodiment of the present invention, the effect component further comprises a second sweetener, the second sweetener is trehalose, and the second sweetener can impart a crystallization inhibiting effect to the orally soluble film, inhibiting the mint Crystallization occurs.

本發明更具體之實施例該效果成份包括吸濕劑,該吸濕劑係選自於氣相法白炭黑、鈉基膨潤土、有機膨潤土、矽藻土、矽酸鋁、矽酸鈣、矽鋁酸鈉、凹凸棒石土、分子篩或矽凝膠群組中之其一,透過該吸濕劑賦予一種口溶膜之油、水吸附能力,減少油相及水相釋出,造成潮溼或膨潤的情況產生。In a more specific embodiment of the present invention, the effect component comprises a moisture absorbent selected from the group consisting of fumed silica, sodium bentonite, organic bentonite, diatomaceous earth, aluminum citrate, calcium citrate, and strontium. One of a group of sodium aluminate, attapulgite, molecular sieve or strontium gel, which imparts oil and water adsorption capacity to an oral solution through the moisture absorbent, reduces oil phase and water phase release, and causes moisture or The situation of swelling occurs.

本發明更具體之實施例更包括第三增稠劑,該第三增稠劑係選自於聚乙烯醇EG-03P(3.0~3.7 mPa・s)、EG-05P(4.8~5.8 mPa・s)、EG-18P(16.0~20.0 mPa・s)、EG-22P(20.0~24.5 mPa・s)、EG-30P(27.0~33.0 mPa・s)、EG-40P(40.0~46.0 mPa・s) 或EG-48P(45.0~52.0 mPa・s)群組中之其一,透過該第三增稠劑賦予一種口溶膜之剛性,減少強度不足的情況產生。A more specific embodiment of the present invention further comprises a third thickener selected from the group consisting of polyvinyl alcohol EG-03P (3.0 to 3.7 mPa·s) and EG-05P (4.8 to 5.8 mPa·s). ), EG-18P (16.0~20.0 mPa·s), EG-22P (20.0~24.5 mPa·s), EG-30P (27.0~33.0 mPa·s), EG-40P (40.0~46.0 mPa·s) or One of the groups of EG-48P (45.0 to 52.0 mPa·s), which imparts rigidity to an orally-soluble film through the third thickener, and reduces the occurrence of insufficient strength.

本發明更具體之實施例該效果成份包括增色劑,該增色劑係選自於紅色六號(0.5)–KIRIYA、紅色六號(1)–MAP、紅色七號(0.5)–KIRIYA、紅色七號(1)–MAP、紅色四十號(1)–MAP、黃色四號(0.5)–KIRIYA、黃色四號(1)–MAP、黃色五號(0.5)–KIRIYA、黃色五號(1)–MAP、綠色B(0.5)或藍色一號(1)–MAP群組中之其一,透過該增色劑賦予一種口溶膜之顏色,增加其視覺的感受。In a more specific embodiment of the invention, the effect component comprises a coloring agent selected from the group consisting of red number six (0.5) - KIRIYA, red number six (1) - MAP, red number seven (0.5) - KIRIYA, red seven No. (1) - MAP, Red Forty (1) - MAP, Yellow No. 4 (0.5) - KIRIYA, Yellow No. 4 (1) - MAP, Yellow No. 5 (0.5) - KIRIYA, Yellow No. 5 (1) One of the MAP, Green B (0.5) or Blue No. 1 (1)-MAP groups, which imparts a color to the orally soluble film through the toner to increase its visual perception.

本發明更具體之實施例該效果成份包括增味劑,該增味劑係選自於甜菊素、山梨醇、甘露醇、麥芽糖醇、木糖醇、甘草甜素、干草葉素、環己氨基磺酸鈉、香蕉香精、葡萄香精、可可香精、菠蘿香精、甜橙香精、水蜜桃香精、蘋果香精、薄荷香精、草莓香精、茴香、香蘭素、檸檬香精、櫻桃香精或玫瑰香精群組中之其一,透過該增味劑賦予一種口溶膜之氣味,增加其嗅覺的感受。In a more specific embodiment of the invention, the effect component comprises a flavor enhancer selected from the group consisting of stevioside, sorbitol, mannitol, maltitol, xylitol, glycyrrhizin, hay extract, cyclohexylamino Sodium sulfonate, banana flavor, grape flavor, cocoa flavor, pineapple flavor, sweet orange flavor, peach flavor, apple flavor, mint flavor, strawberry flavor, fennel, vanillin, lemon flavor, cherry flavor or rose flavor group First, the odorant is imparted with an odor of an orally soluble film to increase the feeling of smell.

本發明更具體之實施例該效果成份包括活性藥物,該活性藥物係選自於對乙酰氨基酚(acetaminophen)、抗壞血酸(ascorbic acid)、無水咖啡因(caffeine anhydrous)、馬來酸氯苯那敏(chlorpheniramine maleate)、氫溴酸右美沙芬(dextromethorphan hydrobromide)、愈創甘油醚(guaifenesin)、L-薄荷/涼感劑(L-menthol / cooling agent)、鹽酸氯苯甲嗪(meclizine HCl)、DL-鹽酸甲基麻黃素(DL-methylephedrine HCl)、鹽酸那可丁(noscapine HCl)、撲熱息痛(paracetamol)、鹽酸偽麻黃鹼(pseudoephedrine HCl)、核黃素(riboflavin)、硝酸硫胺明(thiamine mononitrate) 及鹽酸曲普立定(triprolidine HCl)一種或一種以上之組合,透過該活性藥物賦予一種口溶膜之功效,增加其應用價值。In a more specific embodiment of the invention, the effect component comprises an active drug selected from the group consisting of acetaminophen, ascorbic acid, caffeine anhydrous, and chlorpheniramine maleate. (chlorpheniramine maleate), dextromethorphan hydrobromide, guaifenesin, L-menthol / cooling agent, meclizine HCl, DL - DL-methylephedrine HCl, noscapine HCl, paracetamol, pseudoephedrine HCl, riboflavin, thiamine mononitrate And one or more combinations of triprolidine HCl, which can increase the application value of the oral solution by the active drug.

以下更列舉三個具體之產品以及其製作方法,對本發明加以進一步說明。The present invention will be further described below by exemplifying three specific products and their production methods.

實施例 1Example 1

將3.0wt%羧甲基纖維素鈉及5.0wt%瓜爾豆膠,加入適量無菌水中,進行均質化,製成溶液A;接著,將0.1wt%山梨醇、1.2wt%海藻糖及1.0wt%矽酸鈣,加入適量無菌水中,進行超音波震盪,製成溶液B,將溶液B倒入溶液A;接著,將5.0wt%瓊脂及2.0wt%聚乙烯醇EG-05P,加入溶液A加熱溶解;最後,將0.2wt% 紅色六號、1.0wt% 草莓香精、0.1wt% 無水咖啡因,加入溶液A,進行均質化及除氣;上述作業完成後,便可進行塗佈、烘乾及切片。總重量為100.0wt%,約可製成100片口溶膜,每一片面積10.00cm2,每一片厚度約70μm。3.0 wt% sodium carboxymethylcellulose and 5.0 wt% guar gum were added to an appropriate amount of sterile water for homogenization to prepare a solution A; then, 0.1 wt% sorbitol, 1.2 wt% trehalose and 1.0 wt% were prepared. % calcium citrate, added to the appropriate amount of sterile water, ultrasonic shock, made solution B, poured solution B into solution A; then, 5.0wt% agar and 2.0wt% polyvinyl alcohol EG-05P, added to solution A heating Dissolving; finally, 0.2wt% red No.6, 1.0wt% strawberry flavor, 0.1wt% anhydrous caffeine, added to solution A for homogenization and degassing; after the above operation, coating, drying and slice. The total weight is 100.0% by weight, and about 100 pieces of orally soluble film can be prepared, each having an area of 10.00 cm 2 and each piece having a thickness of about 70 μm.

實施例 2Example 2

將3.0wt%羥乙基纖維素及7.0wt%果膠,加入適量無菌水中,進行均質化,製成溶液A;接著,將0.1wt%阿斯巴甜、5.0wt%海藻糖及0.5wt%矽鋁酸鈉,加入適量無菌水中,進行超音波震盪,製成溶液B,將溶液B倒入溶液A;接著,將5.0wt%黃原膠及2.0wt%聚乙烯醇EG-03P,加入溶液A,加熱溶解;最後,將0.2wt%藍色一號、1.0wt%葡萄香精及0.1wt%抗壞血酸,加入溶液A,進行均質化及除氣;上述作業完成後,便可進行塗佈、烘乾及切片。總重量為100.0wt%,約可製成150片口溶膜,每一片面積7.59cm2 ,每一片厚度約70μm。3.0 wt% hydroxyethyl cellulose and 7.0 wt% pectin were added to an appropriate amount of sterile water to homogenize to prepare a solution A; then, 0.1 wt% of aspartame, 5.0 wt% of trehalose, and 0.5 wt% Sodium strontium aluminate, added to an appropriate amount of sterile water, ultrasonically oscillated to form solution B, and solution B is poured into solution A; then, 5.0 wt% xanthan gum and 2.0 wt% polyvinyl alcohol EG-03P are added to the solution. A, heating and dissolution; finally, 0.2wt% blue No.1, 1.0wt% grape essence and 0.1wt% ascorbic acid are added to solution A for homogenization and degassing; after the above operation is completed, coating and drying can be carried out. Dry and sliced. 100.0 wt% of the total weight, from about 150 can be made orally disintegrating film, an area per 7.59cm 2, each of a thickness of about 70μm.

實施例3Example 3

將2.5wt%羥乙基纖維素及8.0wt%果膠,加入適量無菌水中,進行均質化,製成溶液A;接著,將0.1wt%甜菊糖苷、5.0wt%海藻糖及1.0wt%矽酸鋁,加入適量無菌水中,進行超音波震盪,製成溶液B,將溶液B倒入溶液A;接著,將4.0wt%明膠及1.0wt%聚乙烯醇EG-30P,加入溶液A,加熱溶解;最後,將0.2wt%綠色B、1.0wt%薄荷香精、3.0wt%L-薄荷及1.5wt%涼感劑,加入溶液A,進行均質化及除氣;上述作業完成後,便可進行塗佈、烘乾及切片。總重量為100.0wt%,約可製成200片口溶膜,每一片面積7.59cm2 ,每一片厚度約50μm。2.5 wt% hydroxyethyl cellulose and 8.0 wt% pectin were added to an appropriate amount of sterile water to homogenize to prepare a solution A; then, 0.1 wt% stevioside, 5.0 wt% trehalose, and 1.0 wt% citric acid were added. Aluminum, adding appropriate amount of sterile water, ultrasonic vibration, to make solution B, P solution B into solution A; then, 4.0 wt% gelatin and 1.0 wt% polyvinyl alcohol EG-30P, added to solution A, heated to dissolve; Finally, 0.2wt% green B, 1.0wt% mint flavor, 3.0wt% L-menthol and 1.5wt% cool sensitizer are added to solution A for homogenization and degassing; after the above operation is completed, coating can be carried out. Dry and slice. The total weight is 100.0% by weight, and about 200 pieces of orally soluble film can be prepared, each having an area of 7.59 cm 2 and each piece having a thickness of about 50 μm.

綜上所述,本發明確實符合產業利用性,且未於申請前見於刊物或公開使用,亦未為公眾所知悉,且具有非顯而易知性,符合可專利之要件,爰依法提出專利申請。惟上述所陳,為本發明產業上一較佳實施例,舉凡依本發明申請專利範圍所作之均等變化,皆屬本案訴求標的之範疇。In summary, the present invention is indeed in line with industrial utilization, and is not found in publications or publicly used before application, nor is it known to the public, and has non-obvious knowledge, conforms to patentable requirements, and patents are filed according to law. . However, the above description is a preferred embodiment of the industry of the present invention, and all the equivalent changes made by the scope of the patent application of the present invention are within the scope of the claim.

 

no

Claims (8)

一種口溶膜(an oral dissolving films),包括:
第一增稠劑:介於0.1~5wt%;
係選自於羧甲基纖維素鈉(sodium carboxymethyl cellulose, CMC-Na)、甲基纖維素(methyl cellulose, MC)、羥乙基纖維素(hydroxyethyl cellulose, HEC)、羥丙基纖維素(hydroxypropyl cellulose, HPC)、羥丙基甲基纖維素(hydroxypropyl methyl cellulose, HPMC)、微晶纖維素(microcrystalline cellulose)、變性澱粉(modified starch)、聚丙烯酸鈉(sodium polyacrylate)或聚乙烯吡咯烷酮(polyvinyl pyrrolidone, PVP)群組中之其一;
第二增稠劑:介於0.1~10wt%;
係選自於明膠(gelatin)、乾酪素(casein)、酪蛋白酸鈉(sodium caseinate)、甲殼素(chitin)、殼聚糖(chitosan)、乳清分離蛋白(whey protein isolate)、乳清濃縮蛋白(whey protein concentrate)、魚膠(isinglass)、黃原膠(xanthan gum)、結冷膠(gellan gum)、茁黴多糖(pullulan)、凝結多糖(condensation polysaccharide)、酵母多糖(zymosan)、瓊脂(agar)、卡拉膠(carrageenan)、海藻酸(鹽)(alginic acid (salt))、海藻酸丙二醇酯(propylene glycol alginate)、紅藻膠(furcellaran)或岩藻聚糖硫酸酯(fucoidan);
膠凝劑:介於0.1~10wt%;
選自於瓜爾豆膠(guar gum)、刺槐豆膠(locust bean gum)、羅望子膠(tamarind gum)、亞麻籽膠(flaxseed gum)、皂莢豆膠(honey locust gum)、阿拉伯膠(acacia gum)、黃蓍膠(tragacanth gum)、印度樹膠(Indian gum)、刺梧桐膠(karaya gum)、桃膠(peach gum)、果膠(pectin)、魔芋膠(konjac glucomannan, KGM)、印度蘆薈萃取液(India aloe extract)、菊糖(synanthrin) 或仙草多糖(mesona chinensis polysaccharide);
以及效果成份及水補足至100%。
An oral dissolving film comprising:
First thickener: between 0.1 and 5 wt%;
It is selected from sodium carboxymethyl cellulose (CMC-Na), methyl cellulose (MC), hydroxyethyl cellulose (HEC), hydroxypropyl cellulose (hydroxypropyl). Cellulose, HPC), hydroxypropyl methyl cellulose (HPMC), microcrystalline cellulose, modified starch, sodium polyacrylate or polyvinyl pyrrolidone , PVP) one of the groups;
Second thickener: between 0.1 and 10 wt%;
Is selected from the group consisting of gelatin, casein, sodium caseinate, chitin, chitosan, whey protein isolate, whey concentrate Whey protein concentrate, isinglass, xanthan gum, gellan gum, pullulan, condensation polysaccharide, zymosan, agar (agar), carrageenan, alginate (salt), propylene glycol alginate, furcellaran or fucoidan;
Gelling agent: between 0.1~10wt%;
Selected from guar gum, locust bean gum, tamarind gum, flaxseed gum, honey locust gum, acacia (acacia) Gum), tragacanth gum, Indian gum, karaya gum, peach gum, pectin, konjac glucomannan (KGM), Indian aloe Indra aloe extract, inulinthrin or mesona chinensis polysaccharide;
And the effect ingredients and water make up to 100%.
如申請專利範圍第1項所述之口溶膜,其中該效果成份包括第一甜味劑,該第一甜味劑係選自於玉米糖漿、半乳糖、乳糖、麥芽糖、山梨醇、以酵素轉化之玉米糖漿、葡萄糖、麥芽糖醇、蔗糖、木糖醇、果糖、環己基(代)磺醯胺酸、阿斯巴甜、乙醯磺胺酸鉀、甜菊糖苷、羅漢果、糖精、蔗糖素或5-硝基-2-丙氧基苯胺及紐甜。The orally soluble film according to claim 1, wherein the effect component comprises a first sweetener selected from the group consisting of corn syrup, galactose, lactose, maltose, sorbitol, and an enzyme. Transformed corn syrup, glucose, maltitol, sucrose, xylitol, fructose, cyclohexyl sulfonamide, aspartame, acesulfame potassium, stevioside, mangosteen, saccharin, sucralose or 5 -Nitro-2-propoxyaniline and neotame. 如申請專利範圍第2項所述之口溶膜,其中該效果成份更包括第二甜味劑,該第二甜味劑為海藻糖。The orally soluble film according to claim 2, wherein the effect component further comprises a second sweetener, and the second sweetener is trehalose. 如申請專利範圍第1項所述之口溶膜,該效果成份包括吸濕劑,該吸濕劑係選自於氣相法白炭黑、鈉基膨潤土、有機膨潤土、矽藻土、矽酸鋁、矽酸鈣、矽鋁酸鈉、凹凸棒石土、分子篩或矽凝膠群組中之其一。The oral solution film according to claim 1, wherein the effect component comprises a moisture absorbent selected from the group consisting of fumed silica, sodium bentonite, organic bentonite, diatomaceous earth, and tannic acid. One of a group of aluminum, calcium citrate, sodium strontium aluminate, attapulgite, molecular sieve or strontium gel. 如申請專利範圍第1項所述之口溶膜,更包括第三增稠劑,該第三增稠劑係選自於聚乙烯醇EG-03P(3.0~3.7mPa・s)、EG-05P(4.8~5.8 mPa・s)、EG-18P(16.0~20.0 mPa・s)、EG-22P(20.0~24.5 mPa・s)、EG-30P(27.0~33.0 mPa・s)、EG-40P(40.0~46.0 mPa・s)或EG-48P(45.0~52.0 mPa・s)群組中之其一。The oral solution film according to claim 1, further comprising a third thickener selected from the group consisting of polyvinyl alcohol EG-03P (3.0-3.7 mPa·s), EG-05P. (4.8~5.8 mPa·s), EG-18P (16.0~20.0 mPa·s), EG-22P (20.0~24.5 mPa·s), EG-30P (27.0~33.0 mPa·s), EG-40P (40.0) One of the groups of ~46.0 mPa·s) or EG-48P (45.0~52.0 mPa·s). 如申請專利範圍第1項所述之口溶膜,該效果成份包括增色劑,該增色劑係選自於紅色六號(0.5)–KIRIYA、紅色六號(1)–MAP、紅色七號(0.5)–KIRIYA、紅色七號(1)–MAP、紅色四十號(1)–MAP、黃色四號(0.5)–KIRIYA、黃色四號(1)–MAP、黃色五號(0.5)–KIRIYA、黃色五號(1)–MAP、綠色B(0.5)或藍色一號(1)–MAP群組中之其一。The oral dissolution film according to claim 1, wherein the effect component comprises a coloring agent selected from the group consisting of red No. 6 (0.5) - KIRIYA, red No. 6 (1) - MAP, and red No. 7 ( 0.5) – KIRIYA, Red No. 7 (1) – MAP, Red Forty (1) – MAP, Yellow No. 4 (0.5) – KIRIYA, Yellow No. 4 (1) – MAP, Yellow No. 5 (0.5) – KIRIYA , yellow 5 (1) - MAP, green B (0.5) or blue 1 (1) - one of the MAP groups. 如申請專利範圍第1項所述之口溶膜,該效果成份包括增味劑,該增味劑係選自於甜菊素、山梨醇、甘露醇、麥芽糖醇、木糖醇、甘草甜素、干草葉素、環己氨基磺酸鈉、香蕉香精、葡萄香精、可可香精、菠蘿香精、甜橙香精、水蜜桃香精、蘋果香精、薄荷香精、草莓香精、茴香、香蘭素、檸檬香精、櫻桃香精或玫瑰香精群組中之其一。The oral solution according to claim 1, wherein the effect component comprises a flavor enhancer selected from the group consisting of stevioside, sorbitol, mannitol, maltitol, xylitol, glycyrrhizin, Hay leaf, sodium cyclamate, banana flavor, grape flavor, cocoa flavor, pineapple flavor, sweet orange flavor, peach flavor, apple flavor, mint flavor, strawberry flavor, fennel, vanillin, lemon flavor, cherry flavor Or one of the rose flavor groups. 如申請專利範圍第1項所述之口溶膜,該效果成份包括活性藥物,該活性藥物係選自於對乙酰氨基酚(acetaminophen)、抗壞血酸(ascorbic acid)、無水咖啡因(caffeine anhydrous)、馬來酸氯苯那敏(chlorpheniramine maleate)、氫溴酸右美沙芬(dextromethorphan hydrobromide)、愈創甘油醚(guaifenesin)、L-薄荷/涼感劑(L-menthol / cooling agent)、鹽酸氯苯甲嗪(meclizine HCl)、DL-鹽酸甲基麻黃素(DL-methylephedrine HCl)、鹽酸那可丁(noscapine HCl)、撲熱息痛(paracetamol)、鹽酸偽麻黃鹼(pseudoephedrine HCl)、核黃素(riboflavin)、硝酸硫胺明(thiamine mononitrate)及鹽酸曲普立定(triprolidine HCl)一種或一種以上之組合。The oral solution according to claim 1, wherein the active ingredient comprises an active drug selected from the group consisting of acetaminophen, ascorbic acid, caffeine anhydrous, Chlorpheniramine maleate, dextromethorphan hydrobromide, guaifenesin, L-menthol / cooling agent, chlorpheniramine hydrochloride Meclizine HCl, DL-methylephedrine HCl, noscapine HCl, paracetamol, pseudoephedrine HCl, riboflavin, nitric acid One or a combination of thiamine mononitrate and triprolidine HCl.
TW104128011A 2015-08-26 2015-08-26 Mouth soluble film TWI612978B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
TW104128011A TWI612978B (en) 2015-08-26 2015-08-26 Mouth soluble film

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TW104128011A TWI612978B (en) 2015-08-26 2015-08-26 Mouth soluble film

Publications (2)

Publication Number Publication Date
TW201707691A true TW201707691A (en) 2017-03-01
TWI612978B TWI612978B (en) 2018-02-01

Family

ID=58774354

Family Applications (1)

Application Number Title Priority Date Filing Date
TW104128011A TWI612978B (en) 2015-08-26 2015-08-26 Mouth soluble film

Country Status (1)

Country Link
TW (1) TWI612978B (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019049103A1 (en) * 2017-09-11 2019-03-14 Universidade Católica Portuguesa Oral compositions, methods and uses thereof
EP3893823A4 (en) * 2018-12-11 2022-11-02 Myospots Australia Pty Ltd Adhesive pad
RU2806499C2 (en) * 2018-12-11 2023-11-01 Майоспотс Острейлиа Пти Лтд Adhesive pad

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201012468A (en) * 2008-09-17 2010-04-01 Orient Pharma Co Ltd Release-controlled type matrix tablet containing Paroxetine
KR101074271B1 (en) * 2009-06-25 2011-10-17 (주)차바이오앤디오스텍 Fast dissolving oral dosage form containing steviosides as a taste masking agent
HU1000278D0 (en) * 2010-05-28 2010-07-28 Egis Gyogyszergyar Nyilvanosan Novel pharmaceutical use uf silicic acid
CN104546807B (en) * 2015-01-21 2020-09-01 齐鲁制药有限公司 Olanzapine oral instant film agent

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019049103A1 (en) * 2017-09-11 2019-03-14 Universidade Católica Portuguesa Oral compositions, methods and uses thereof
EP3893823A4 (en) * 2018-12-11 2022-11-02 Myospots Australia Pty Ltd Adhesive pad
RU2806499C2 (en) * 2018-12-11 2023-11-01 Майоспотс Острейлиа Пти Лтд Adhesive pad

Also Published As

Publication number Publication date
TWI612978B (en) 2018-02-01

Similar Documents

Publication Publication Date Title
JP3460538B2 (en) Fast dissolving film preparation
JP5213446B2 (en) Pharmaceutical composition comprising diclofenac
EP2431028B1 (en) Fast-dissolving oral film for effectively concealing unpleasant tastes
JP6198370B2 (en) Oral dosage form
RU2437648C2 (en) Foamed lozenge containing grafted copolymer of polyvinyl alcohol and polyethylene glycol
Gauri et al. Fast dissolving drug delivery and its technologies.
JP5941558B2 (en) High content fast dissolving film containing sildenafil as an active ingredient and concealing bitterness
US20140335153A1 (en) Thin film with high load of active ingredient
CN105997955B (en) A kind of Palonosetron oral cavity membrane and preparation method thereof
JP2002275066A (en) Patch for mucous membrane
US9789112B2 (en) Oral pharmaceutical film formulation for bitter tasting drugs
EP3532035B1 (en) Compositions of different densities for fast disintegrating multi-layer tablet
KR20100032883A (en) Medicinal film preparation with rapidly dissolving property and flexibility
JP5624472B2 (en) Loperamide hydrochloride-containing film preparation
Gijare et al. Orodispersible Films: A systematic patent review
TWI612978B (en) Mouth soluble film
JP5284070B2 (en) Oral mucosa patch preparation
Saxena et al. Oral dissolving films: a comprehensive review on recent perspectives and current approach to effective drug delivery
CN105012276A (en) Imidafenacin oral fast dissolving film and preparation method and application thereof
US20130216594A1 (en) Preparation of orodispersible films
JP2012031164A (en) Film-shaped preparation
KR102153894B1 (en) Oral disintegrating film formulation comprising ondansetron or its salt and process for preparing the same
Balaji et al. Fast dissolving oral films for immediate drug release: a review
Dave et al. A review on promising novel drug delivery system-bioadhesive drug delivery system
TWI835118B (en) Brexpiprazole oral film inclusion complex, preparation method and use thereof